GHRH improves cognitive performance and some endocrine values in healthy elderly people and in those with MCI.
Somatotrophic hormones, including growth hormone (GH), insulinlike growth factor 1 (IGF-1), and growth hormone–releasing hormone (GHRH), decrease with aging and may have a role in cognitive impairments. In a double-blind, placebo-controlled study, researchers examined the effect of manufacturer-supplied GHRH (1 mg/day) administered subcutaneously before bed for 20 weeks in 66 participants with amnestic mild cognitive impairment (MCI) and 86 healthy participants (mean age, 68). Researchers performed multiple assessments of IGF-1 levels, endocrine assessments at baseline and at week 20, and neuropsychiatric assessments at baseline, at weeks 10 and 20, and at 10 weeks after discontinuation (week 30).
In both healthy and MCI groups, GHRH was ass…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)